Erenumab for Chronic Cluster Headache: A Randomized Clinical Trial.

ABSTRACT:

Importance

Calcitonin gene-related peptide (CGRP) is involved in the pathophysiology of cluster headache (CH). Prophylactic pharmacologic treatment options for chronic CH (CCH) are limited. The potential effects of erenumab, a CGRP receptor antagonist monoclonal antibody, in treating CCH have not been assessed.

Objective

To evaluate the superiority of erenumab compared with placebo in the prophylaxis of CCH.

Design, setting, and participants

A 12-week, double-blind, placebo-controlled randomized clinical trial (CHERUB01) was conducted at 11 sites in Germany from December 2, 2021, to September 27, 2023. Participants (aged 18-65 years) had a diagnosis of CCH, had no previous sufficient response to standard CCH prophylactic medications approved in Germany, and had experi

SUBMITTER: Mecklenburg J 

PROVIDER: S-EPMC12175031 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature